Mars Mesothelioma Trial, Frontiers Emerging Treatments For Malignant Pleural Mesothelioma Where Are We Heading Oncology

Mesothelioma and radical surgery 2.

Free coloring pages for adults animals. The trial is supported by cancer research uk. The mars mesothelioma and radical surgery trial is recruiting in the uk with the intention that if its implementation proves feasible it will become an international trial. Estimated primary completion date.

Patients aged 18 years or older who had pathologically confirmed mesothelioma and were deemed fit enough to undergo trimodal therapy were included. Uk based clinical trial the mesothelioma and radical surgery trial 2 mars 2. Estimated study completion date.

A multicentre randomised trial comparing extended pleurectomy decortication versus no extended pleurectomy decortication for patients with malignant pleural mesothelioma mars 2. Several phase 2 studies have been reported on the role of neoadjuvant chemotherapy epp and postoperative radiotherapy. Trial recruitment was facilitated within centres by the national institute for health research funded national cancer research network.

Mesothelioma and radical surgery trial mars disease site. The purpose of the qas was to. The trial experienced practical issues including lengthy recruitment and non compliance with randomisation six out of 26 participants.

It is a difficult study but we did not choose surgery because it is an easy life. Methods and analysis the mars 2 study is a uk multicentre open parallel group randomised controlled trial comparing the effectiveness and cost effectiveness of surgeryextended pleurectomy decorticationversus no surgery for the treatment of pleural mesothelioma. This trial is for people who have pleural mesothelioma that is only affecting one side of the chest.

Mesothelioma is a type of cancer that can develop in the covering of the lungs pleural mesothelioma. Study start date. The only randomised trial to assess epp in mpm was the mesothelioma and radical surgery trial mars a feasibility study whose primary aim was to determine whether a full scale trial would be possible.

Mars was supported by cancer research uk grant number cruk04003 with additional support from the june hancock mesothelioma research fund. These studies have included patients with t13 tumours but differed in the inclusion of n2 status and sarcomatoid. The mars2 trial assessed the role of lung sparing surgery and chemotherapy compared to chemotherapy alone for the treatment of malignant pleural mesothelioma.

Lung cancer other cancers treatment modality. We aimed to assess the clinical outcomes of patients who were randomly assigned to epp or no epp in the context of trimodal therapy in the mesothelioma and radical surgery mars feasibility study. The value of extrapleural pneumonectomy epp in the context of multimodality therapy for patients with malignant pleural mesothelioma is controversial.

Also icr ctsu receives core support from cancer research uk.